Search research articles
Contact Us
Filters
Showing results (161-170 of 361) with videos related to
Page
of 37
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2004
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)
Eric J Small, Susan Halabi, Nancy A Dawson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 21, 2006
Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study
Brian I Rini, Susan Halabi, Robert Barrier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 22, 2005
Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study
Robert W Ross, Susan Halabi, San-San Ou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2003
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer
Susan Halabi, Eric J Small, Philip W Kantoff, et al.
Journal of the National Cancer Institute
|
February 16, 2013
Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy
Andrea B Apolo, Irina Ostrovnaya, Susan Halabi, et al.
Clinical Genitourinary Cancer
|
October 1, 2008
A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004
Nancy A Dawson, Susan Halabi, San-San Ou, et al.
Cancer
|
July 23, 2008
Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer
Celestia S Higano, John M Corman, David C Smith, et al.
Ebiomedicine
|
February 13, 2016
A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance)
Hyung L Kim, Susan Halabi, Ping Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 2002
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480
Eric J Small, Susan Halabi, Mark J Ratain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 2006
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
Eric J Small, Paul F Schellhammer, Celestia S Higano, et al.
Page
of 37
Search research articles
Search
Showing results (161-170 of 361) with videos related to
Sort By:
Page
of 37
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2004
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)
Eric J Small, Susan Halabi, Nancy A Dawson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 21, 2006
Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study
Brian I Rini, Susan Halabi, Robert Barrier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 22, 2005
Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study
Robert W Ross, Susan Halabi, San-San Ou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2003
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer
Susan Halabi, Eric J Small, Philip W Kantoff, et al.
Journal of the National Cancer Institute
|
February 16, 2013
Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy
Andrea B Apolo, Irina Ostrovnaya, Susan Halabi, et al.
Clinical Genitourinary Cancer
|
October 1, 2008
A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004
Nancy A Dawson, Susan Halabi, San-San Ou, et al.
Cancer
|
July 23, 2008
Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer
Celestia S Higano, John M Corman, David C Smith, et al.
Ebiomedicine
|
February 13, 2016
A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance)
Hyung L Kim, Susan Halabi, Ping Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 2002
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480
Eric J Small, Susan Halabi, Mark J Ratain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 2006
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
Eric J Small, Paul F Schellhammer, Celestia S Higano, et al.
Page
of 37